References
- DanceyJmTOR signaling and drug development in cancerNat Rev Clin Oncol20107420921920234352
- Meric-BernstamFGonzalez-AnguloAMTargeting the mTOR signaling network for cancer therapyJ Clin Oncol200927132278228719332717
- LebwohlDAnakOSahmoudTDevelopment of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseasesAnn N Y Acad Sci20131291143223659703
- TaberneroJRojoFCalvoEDose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJ Clin Oncol200826101603161018332469
- O’DonnellAFaivreSBurrisHAPhase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsJ Clin Oncol200826101588159518332470
- KruegerDACareMMHollandKEverolimus for subependymal giant-cell astrocytomas in tuberous sclerosisN Engl J Med2010363191801181121047224
- BisslerJJKingswoodJCRadzikowskaEEverolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialLancet2013381986981782423312829
- AFINITOR® (everolimus) tablets for oral administrationAFINITOR DISPERZ (everolimus tablets for oral suspension) [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2014
- ZORTRESS® (everolimus) tablets for oral use [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2013
- RavaudAUrvaSRGroschKCheungWKAnakOSellamiDBRelationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncologyEur J Cancer201450348649524332451
- SankhalaKMitaAKellyKMahalingamDGilesFMitaMThe emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsTarget Oncol20094213514219381454